Overcoming translational challenges to advance cell therapy for neonatal brain injury

"...the conversation is shifting towards how we can provide broad and equitable patient access to these therapies...”

HAON Life Sciences, which leads the CanVas consortium and is focused on developing a cell therapy targeting infant brain injury, has recently received a €10.7 million non-dilutive grant through the Disruptive Technologies Innovation Fund, which is managed by the Department of Enterprise, Trade and Employment in Ireland and administered by Enterprise Ireland. In this interview, Jokūbas Leikauskas, Editor, BioInsights, speaks to Mikey Creane, Translational Research Manager, HAON Life Sciences, about the progress of the company’s cell therapy for neonatal hypoxic-ischemic encephalopathy (HIE) and strategies to overcome translational challenges and accelerate clinical development.

Please enter your email to access content Read now